Duvelisib: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Duvelisib. Educational only — not medical advice.
Labeled uses
COPIKTRA is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least two prior lines of systemic therapy. Limitations of Use: COPIKTRA is not indicated or recommended for the treatment of any patients with CLL or SLL as initial or second line treatment due to an increased risk of treatment-related mortality.
Source: FDA labeling via NIH DailyMed (set e3c5ac56…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.